Fate Therapeutics vs Molecular Partners
FATE and MOLN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How FATE and MOLN compare
Fate Therapeutics grew revenue faster over the last twelve months (−33.4% versus −100% for Molecular Partners).
Fate Therapeutics scores higher on the StockData Score (6 against 1 for Molecular Partners), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | FATE | MOLN |
|---|---|---|
| Size and price | ||
| Market cap | $161M | – |
| Share price | $1.34 | $3.01 |
| Change, 1 year | 19.6% | −25.3% |
| Change, 5 years | −97.6% | −71.2% |
| Beta (5Y) | 2.40 | 0.88 |
| Employees | 161 | 34 |
| StockData Score | ||
| Total score | 6 (better) | 1 |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 33.8× | – |
| P/B | 1.2× | – |
| FCF yield | −66.5% | – |
| Fair value | $1.13 | – |
| Margin of safety | −18.6% | – |
| Growth | ||
| Revenue growth (TTM) | −33.4% (better) | −100% |
| Revenue growth, 5Y average | −26.7% | – |
| Profitability | ||
| Operating margin | −2760% | – |
| Net margin | −2620% | – |
| FCF margin | −2249% | – |
| Return on equity | −67.8% | – |
| Return on invested capital | −1647% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −11.5× |
| Current ratio | 4.41 | 7.27 (better) |
| Altman Z-score | −9.87 | – |
| Piotroski F-score | 3 | – |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 59.9% | 8.9% |
| Held by insiders | 25.7% | 0.00% |
| Insider net buying, 12 months | −$336K | – |
| Short interest, % of float | 11.2% | – |
Go deeper
- FATE stock overview
- FATE income statement
- FATE valuation and score
- MOLN stock overview
- MOLN income statement
- MOLN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.